SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals, is committed to accelerating the development of innovative treatments for central nervous system (CNS) disorders and oncology. Both companies are a part of SK Group, one of the largest conglomerates in Korea, a global leader in energy, chemical, semiconductor and telecommunications industries, and one of TIME’s 100 Most Influential Companies of 2023. SK Life Science, Inc., is headquartered in Paramus, New Jersey. SK Life Science and SK Biopharmaceuticals have eight compounds in development globally for the treatment of CNS disorders including epilepsy, attention-deficit hyperactivity disorder, schizophrenia, bipolar disorder, and oncology among others. For more information, please visit https://www.sklifescienceinc.com/innovation/#/pipeline. View our community guidelines here: bit.ly/447WI1A